Romifidine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Romifidine
Accession Number
DB11543
Type
Small Molecule
Groups
Vet approved
Description

Romifidine is a veterinary drug utilized as a sedative primarily in large animals, most frequently horses. It is also used less commonly in a wide variety of other animal species. This drug's chemical structure closely resembles that of clonidine, however, romifidine is not approved for use in humans.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Romifidine hydrochloride98LQ6RS0TA65896-14-2SDXVSIWCVTYYQN-UHFFFAOYSA-N
International/Other Brands
Sedivet
Categories
UNII
876351L05K
CAS number
65896-16-4
Weight
Average: 258.094
Monoisotopic: 256.996388
Chemical Formula
C9H9BrFN3
InChI Key
KDPNLRQZHDJRFU-UHFFFAOYSA-N
InChI
InChI=1S/C9H9BrFN3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
IUPAC Name
N-(2-bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine
SMILES
FC1=CC=CC(Br)=C1NC1=NCCN1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic AcidThe risk or severity of hypertension can be increased when 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid is combined with Romifidine.
1-benzylimidazoleThe risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Romifidine.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Romifidine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Romifidine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Romifidine.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Romifidine.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Romifidine is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Romifidine.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Romifidine.
AbediterolThe risk or severity of hypertension can be increased when Romifidine is combined with Abediterol.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. England GC, Watts N: Effect of romifidine and romifidine-butorphanol for sedation in dogs. J Small Anim Pract. 1997 Dec;38(12):561-4. [PubMed:9444638]
  2. England GC, Flack TE, Hollingworth E, Hammond R: Sedative effects of romifidine in the dog. J Small Anim Pract. 1996 Jan;37(1):19-25. [PubMed:8642795]
  3. Browning AP, Collins JA: Sedation of horses with romifidine and butorphanol. Vet Rec. 1994 Jan 22;134(4):90-1. [PubMed:8178417]
  4. Pypendop BH, Verstegen JP: Cardiovascular effects of romifidine in dogs. Am J Vet Res. 2001 Apr;62(4):490-5. [PubMed:11327453]
  5. Selmi AL, Barbudo-Selmi GR, Moreira CF, Martins CS, Lins BT, Mendes GM, McManus C: Evaluation of sedative and cardiorespiratory effects of romifidine and romifidine-butorphanol in cats. J Am Vet Med Assoc. 2002 Aug 15;221(4):506-10. [PubMed:12184699]
  6. Aithal HP, Amarpal, Kinjavdekar P, Pawde AM, Pratap K: Analgesic and cardiopulmonary effects of intrathecally administered romifidine or romifidine and ketamine in goats (Capra hircus). J S Afr Vet Assoc. 2001 Jun;72(2):84-91. [PubMed:11513266]
  7. Freeman SL, Bowen IM, Bettschart-Wolfensberger R, Alibhai HI, England GC: Cardiovascular effects of romifidine in the standing horse. Res Vet Sci. 2002 Apr;72(2):123-9. [PubMed:12027592]
  8. Marzok M, El-Khodery S: Sedative and analgesic effects of romifidine in camels (Camelus dromedarius). Vet Anaesth Analg. 2009 Jul;36(4):352-60. doi: 10.1111/j.1467-2995.2009.00473.x. [PubMed:19538572]
  9. Selmi AL, Figueiredo JP, Mendes GM, Lins BT: Effects of tiletamine/zolazepam-romifidine-atropine in ocelots (Leopardus pardalis). Vet Anaesth Analg. 2004 Jul;31(3):222-6. [PubMed:15268694]
  10. Gomez-Villamandos RJ, Redondo JI, Martin EM, Dominguez JM, Granados MM, Estepa JC, Ruiz I, Aguilera E, Santisteban JM: Romifidine or medetomidine premedication before propofol-sevoflurane anaesthesia in dogs. J Vet Pharmacol Ther. 2005 Oct;28(5):489-93. [PubMed:16207314]
External Links
KEGG Drug
D08487
ChemSpider
64975
ChEMBL
CHEMBL2105424
Wikipedia
Romifidine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0859 mg/mLALOGPS
logP2.21ALOGPS
logP2.19ChemAxon
logS-3.5ALOGPS
pKa (Strongest Basic)8.06ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area36.42 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity57.32 m3·mol-1ChemAxon
Polarizability21.06 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aniline and substituted anilines. These are organic compounds containing an aminobenzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Aniline and substituted anilines
Direct Parent
Aniline and substituted anilines
Alternative Parents
Fluorobenzenes / Bromobenzenes / Aryl fluorides / Aryl bromides / Imidazolines / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
Aniline or substituted anilines / Bromobenzene / Fluorobenzene / Halobenzene / Aryl bromide / Aryl fluoride / Aryl halide / 2-imidazoline / Guanidine / Azacycle
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on February 26, 2016 10:41 / Updated on June 04, 2019 07:23